Author

A. C. Ramon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:differential expression· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

G. V. Perez· 4 shared M. Rosales· 4 shared S. E. Perea· 4 shared Y. Perera· 4 shared Y. Ramos· 3 shared A. Rodriguez-Ulloa· 2 shared D. Aguilar· 2 shared D. Vazquez-Blomquist· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

G. V. Perez

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells

D. Vazquez-Blomquist, A. C. Ramon, M. Rosales, G. V. Perez, A. Rosales, D. Palenzuela, Y. Perera, S. E. Perea

This study uses microarray profiling to analyze the time-dependent gene expression changes in AML cell lines treated with CIGB-300, identifying modulated genes and pathways involved in apoptosis, cell cycle, and inflammation.

bioRxiv · Mar 6, 2023 · PreprintCancer Biology

Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection

A. C. Ramon, G. V. Perez, E. Caballero, M. Rosales, D. Aguilar, D. M. Vazquez-Blomquist, Y. Ramos, A. Rodriguez, V. Falcon, M. P. Rodriguez, Y. Ke, Y. Perera, S. E. Perea

This study shows that CIGB-325, an anti-CK2 peptide, inhibits bovine coronavirus infection by reducing viral protein accumulation and cytopathic effects.

bioRxiv · Jun 8, 2021Pharmacology & Toxicology

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

M. Rosales, G. V. Perez, A. C. Ramon, Y. Cruz, A. Rodriguez-Ulloa, V. Besada, Y. Ramos, D. Vazquez-Blomquist, E. Caballero, D. Aguilar, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Ke, Y. Perera, S. E. Perea

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

bioRxiv · May 19, 2021Cancer Biology

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

M. Rosales, A. Rodriguez-Ulloa, V. Besada, A. C. Ramon, G. V. Perez, Y. Ramos, O. Guirola, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Perera, S. E. Perea

This study examines the phosphoproteomic changes in AML cell lines treated with CX-4945, identifying key biological processes and pathways affected by CK2 inhibition.

bioRxiv · Jan 4, 2021Cancer Biology